Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice

Dawn Thompson(University of Aberdeen), Nimesh Mody(University of Aberdeen)

Research Square

November 4, 2022

10.21203/rs.3.rs-2183793/v1

Cited by 0

Related Papers

Susceptibility to diet-induced obesity and glucose intolerance in the APP SWE/PSEN1 A246E mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein

|Diabetologia|2011|81

Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR−/− mouse model of atherosclerosis

|Clinical Science|2017|36

Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice

|Scientific Reports|2023|16

GRK5 regulates endocytosis of FPR2 independent of β-arrestins

|Journal of Biological Chemistry|2024|5

Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice

|bioRxiv (Cold Spring Harbor Laboratory)|2022|1